Kinepolis Group NV (KIN)
Euronext Brussels · Belgium · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 47.60 |
|---|---|
| 52-week range | 23.70 – 52.40 |
| Return, 1 month / 3 months | −6.1% / +24.9% |
| Return, 1 year / 3 years | +62.2% / +7.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 40 |
| Volatility (1 year) | 26.3% |
| Worst drawdown (1 year) | -22.6% |
| Average daily value traded | 2.33M EUR |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kinepolis Group is a cinema operator based in Belgium that runs multiplex theatres showing films to general audiences. Its cinemas offer comfortable auditoriums with large screens and sound systems, along with concessions and spaces that can be hired for private screenings and events. The company operates cinemas in Belgium and several other European countries as well as in North America, serving moviegoers in cities and towns where its theatres are located.
On this site Kinepolis Group NV appears as a stock on the Euronext Brussels (Belgium), code KIN, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kinepolis Group NV (KIN) trades on the Euronext Brussels in Belgium. It last closed at EUR 47.60 on 23 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 11 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 62.2% and over the last three months it rose 24.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 35.6% | ||
| From 52-week high | -7.8% | ||
| Momentum | 99 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 24.9% | ||
| 6-month return | 64.1% | ||
| 12-month return, skipping the last month | 72.8% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.6% | ||
| Liquidity | 81 · Strong | Trades actively. | |
| Average daily value traded | 2.33M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 14 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −4.5% |
|---|---|
| 1 month | −6.1% |
| 3 months | +24.9% |
| 6 months | +64.1% |
| 1 year | +62.2% |
| 3 years | +7.9% |
| 5 years | −5.9% |
Signals
| 50-day / 200-day average | 48.38 / 35.10 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.24 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 0.6500 |
| 16 May 2025 | EUR 0.5500 |
| 13 May 2024 | EUR 0.5500 |
| 12 May 2023 | EUR 0.2600 |
| 15 May 2020 | EUR 1.0000 |
| 10 May 2019 | EUR 0.9200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.